French diagnostics company bioMérieux (Euronext Paris:BIM) announced on Monday the acquisition of key assets from Day Zero Diagnostics, a US-based infectious disease diagnostics company that uses genome sequencing and machine learning to tackle the rise of antibiotic-resistant infections.

The acquisition includes Day Zero Diagnostics' proprietary next-generation sequencing workflows, chemistries, reagents, bioinformatics pipeline and software. These solutions remain in development but are designed to identify bacterial species and their antibiotic resistance profiles directly from blood samples within hours. This represents a significant improvement over current diagnostic methods, which typically require 2 to 5 days for similar results.

bioMérieux aims to integrate these technologies to enhance its R&D capabilities and advance rapid infectious disease diagnostics.

The move supports bioMérieux's strategy to address critical healthcare challenges such as antimicrobial resistance and sepsis.